However, tandem therapies of Kv1.3 and KCa1.1 blockers were even more beneficial than the monotherapies, indicating the value of directly targeting both TEM cells and FLS as a novel and potent therapeutic approach to treating RA. This evidence concerns the gene KCNMA1 and rheumatoid arthritis.